Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5815 - Correlation between ctDNA methylation and CEA in colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Weiwei Tang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

W. Tang1, H. An1, D. Zhou2, M. Cai1, R. Zeng1, X. Lv3, L. Chen1, F. Ye1, Y. Zhang4

Author affiliations

  • 1 Department Of Medical Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, 361000 - Xiamen/CN
  • 2 Department Of Medical Oncology, Xiang'an Hospital of Xiamen University, 361000 - Xiamen/CN
  • 3 Department Of Medical Oncology, Xiamen Humanity Hospital, 361000 - Xiamen/CN
  • 4 Key Laboratory Of Design And Assembly Of Functional Nanostructures, Fujian Provincial Key Laboratory Of Nanomaterials, Fujian Institute of Research on the Structure of Matter, Chinese Academy of Sciences, 361000 - Xiamen/CN
More

Resources

Abstract 5815

Background

Compared with the classical tumor markers, ctDNA has higher accuracy and specificity while being noninvasive. Based on the prophase work, we explore the role of ctDNA methylation in the detection of PCDH18 as a new tumor marker compared with CEA in the clinical diagnosis and progressive evaluation of colorectal cancer (CRC).

Methods

We collected peripheral blood from 60 patients with advanced primary CRC before and after two courses of treatment, as well as from 60 healthy individuals, and the clinicopathologic characteristics were analyzed. The changes of CEA levels before and after treatment were dynamically monitored by electrochemiluminescence (ECL). The methylation status of PCDH18 was detected by qMSP, the correlation between them was also statistically analyzed, and the value of different indexes in the diagnosis and monitoring of tumor progression of CRC were compared.

Results

We found that the percentage of methylation of PCDH18 in plasma of CRC before treatment was significantly higher than that of normal plasma samples. The difference (p < 0.01) suggests that PCDH18 methylation may be involved in the carcinogenesis of CRC. PCDH18 methylation was not significantly correlated with sex, tumor location, histological type, tumor differentiation, TNM or CEA(P > 0.05). To further explore the relationship between the methylation of PCDH18 and the risk of CRC, the results showed that with the increase of methylation level of PCDH18, the risk of CRC and tumor progression increased significantly, while in CEA group, the OR > 1 only in the group with CEA elevation as the dividing point, but the P value was not statistically significant. The sensitivity and specificity of PCDH18 ctDNA methylation combined with CEA in the diagnosis of progression of CRC were 90.0% and 67.6%, respectively. The area under the curve (AUC) reached 0.861. Further analysis showed that PCDH18 ctDNA methylation was 67.86% while CEA was negative in CRC progression patients, indicating that PCDH18 ctDNA methylation could significantly increase the detection of progression in comparison with CEA.

Conclusions

The methylation of PCDH18 ctDNA may play an important role in the diagnosis and prediction of tumor progression in CRC as a new tumor marker and can significantly increase the detection of tumor progression in CEA-negative patients. W-W. Tang, H-X. An and D. Zhou contributed equally to this work.

Clinical trial identification

Legal entity responsible for the study

Clinical research Ethics Committee of the First Affiliated Hospital of Xiamen University.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81702414), the Fujian Provincial Health and Family Planning Commission Foundation of Youth scientific research project (No. 2015-2-43) and Xiamen Science and Technology Bureau Foundation of science and technology project for the benefit of the people (No. 3502Z20164010).

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.